Dr Phillip J. Koo provides his thoughts on the use of advanced PET imaging in prostate cancer


Introducing the RADAR studies

Dr Phillip J. Koo provides his thoughts on the use of advanced PET imaging in prostate cancer. He covers when to use these tools by examining the published data, specifically the RADAR 1 and 3 studies. The RADAR (radiographic assessments for detection of advanced recurrence) group, are a team of experts, including Dr Koo, who have published articles pertinent to prostate cancer imaging. The initial paper of RADAR 1 reviewed imaging guidelines with associated clinical validation studies for metastatic prostate cancer. It provided recommendations for clinical practice to improve early detection of metastatic disease. RADAR III focuses on updates regarding next generation imaging for improved guidance.

Important findings for imaging metastatic prostate cancer

In this video and associated slides, Dr Koo details the RADAR 1 and 3 recommendations, comparing conventional imaging to advanced PET imaging for detection of metastatic disease in prostate cancer. Prostate cancer PET detection rates as a function of PSA in patients with biochemical recurrence are addressed. The suitability of radiotracers for next generation imaging is discussed, and how to approach different patient groups. Lastly, what test to use based on availability, accounting for location and coverage by MEDICARE. View the video and slides provided as part of our educational resources and practical guidance for medical oncologists and urologists.

Phillip J. Koo, MD is the Division Chief of Diagnostic Imaging at the Banner MD Anderson Cancer Center in Arizona. Prior to this, he was Chief of Nuclear Medicine and Associate Professor of Radiology at the University of Colorado School of Medicine. Dr Koo completed his transitional internship at the University of Pennsylvania Medical Center-Presbyterian, radiology residency at Pennsylvania Hospital of the University of Pennsylvania Health System, and fellowship at the Harvard Medical School Joint Program in Nuclear Medicine. He is a diplomate of both the American Board of Radiology (ABR) and American Board of Nuclear Medicine. Dr Koo is an active member of multiple societies and serves on the Scientific Program Committee for the Radiological Society of North America, Nuclear Radiology Certifying Exam Committee for the ABR, and is the Chair of the Quality and Evidence Committee for the Society of Nuclear Medicine and Molecular Imaging (SNMMI).  He is also Chair of the Prostate Cancer Working Group at the SNMMI and was a member of the RADAR I and II working groups. Dr Koo has published on various topics related to radiology and nuclear medicine in multiple journals such as Radiology, Radiographics, European Journal of Nuclear Medicine and Molecular Imaging, Urology, and Journal of the American College of Radiology.  

Dr Phillip Koo has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

AstraZeneca, Bayer, Blue Earth, Janssen, Lantheus, Merck and Novartis. 

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts

Other programmes of interest

video Video
Oncology 
ER+ metastatic breast cancer: Elacestrant and beyond

Follow a patient's journey during and post-elacestrant treatment for ER+/HER2- metastatic breast cancer

Experts
Prof. Maria Vittoria Dieci
Endorsed by
GRASP
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Feb 2024

Educational programme supported by an independent medical education grant from Menarini Stemline Oncology.
podcast Podcast

Episode

3

of 3

episode
Oncology 
Ovarian Cancer: Pre-analytical phase challenges and biomarker testing

Experts
Assoc. Prof. Martina Murphy, Assoc. Prof. Caterina Marchiò, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 32 MIN
  • calendar Feb 2024

Educational programme supported by an independent medical education grant from AstraZeneca and Amoy Diagnostics.
micro-learning Micro learning

Module

2

of 2

module
Oncology 
PARP inhibitors in prostate cancer and the rationale behind combination treatment

Module 2 - Evolving landscape of PARPi in mCRPC: Combination with anti-androgens

Experts
Assoc. Prof. Alicia Morgans, Dr Pasquale Rescigno
Endorsed by
ZERO EAUN
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Jan 2024

Educational programme supported by an independent medical education grant from AstraZeneca
micro-learning Micro learning

Module

1

of 2

module
Oncology 
PARP inhibitors in prostate cancer and the rationale behind combination treatment

Module 1 - PARP inhibitors in advanced prostate cancer

Experts
Assoc. Prof. Alicia Morgans, Dr Pasquale Rescigno
Endorsed by
ZERO EAUN
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Jan 2024

Educational programme supported by an independent medical education grant from AstraZeneca
interactive-patient-case Interactive patient case

Episode

2

of 2

episode
Oncology 
Advanced HCC: Treatment options for patients ineligible for IO

Explore treatment options, adverse event management and next steps in this interactive patient case

Experts
Prof. Sammy Saab
Endorsed by
Blue Faery Digestive Cancers Europe 5th anniversary
Global Liver Institute
  • clock 15 MIN
  • calendar Jan 2024

Educational programme supported by an independent medical education grant from Bayer.
podcast Podcast

Episode

2

of 3

episode
Oncology 
Lung Cancer: Pre-analytical phase challenges and biomarker testing

Moderated by the Oncology Brothers. Episode 2 of a 3-part video podcast series

Experts
Dr Bruna Pellini, Dr Semir Vranić, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Jan 2024

Educational programme supported by an independent medical education grant from AstraZeneca and Amoy Diagnostics.